Genocea Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2022 was $7.11 Mil. Genocea Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2022 was $8.37 Mil. Genocea Biosciences's Total Stockholders Equity for the quarter that ended in Mar. 2022 was $12.39 Mil.
Genocea Biosciences's debt to equity for the quarter that ended in Mar. 2022 was 1.25.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Genocea Biosciences's Debt-to-Equity or its related term are showing as below:
Genocea Biosciences Debt-to-Equity Historical Data
The historical data trend for Genocea Biosciences's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
Genocea Biosciences Annual Data
|
|
Trend |
Dec12 |
Dec13 |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
| Debt-to-Equity |
|
Get a 7-Day Free Trial
|
|
|
-2.37 |
2.02 |
0.80 |
2.66 |
0.64 |
|
Genocea Biosciences Quarterly Data
|
|
Jun17 |
Sep17 |
Dec17 |
Mar18 |
Jun18 |
Sep18 |
Dec18 |
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
| Debt-to-Equity |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
11.15 |
4.75 |
0.50 |
0.64 |
1.25 |
Competitive Comparison
For the Biotechnology subindustry, Genocea Biosciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genocea Biosciences Debt-to-Equity Distribution
For the Biotechnology industry and Healthcare sector, Genocea Biosciences's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Genocea Biosciences's Debt-to-Equity falls into.
Genocea Biosciences Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Genocea Biosciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2021 is calculated as
Genocea Biosciences's Debt to Equity Ratio for the quarter that ended in Mar. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genocea Biosciences (Genocea Biosciences) Business Description
Traded in Other Exchanges
N/A
Address
100 Acorn Park Drive, Cambridge, MA, USA, 02140
Genocea Biosciences Inc is a US-based biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs. Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns a pre-clinical immuno-oncology program focused on personalized cancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines.
Executives
| Jacquelyn L Sumer |
officer: CHIEF LEGAL & COMPLIANCE OFF |
C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140 |
| William D Clark |
director, officer: President and CEO |
C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140 |
| George Siber |
director |
2000 BROADWAY, PENTHOUSE 2B, NEW YORK NY 10023 |
| Diantha Duvall |
officer: CHIEF FINANCIAL OFFICER |
C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140 |
| Scott D Sandell |
10 percent owner |
|
| Stapleton Raymond D Jr |
officer: EVP PHARM SCI & MFG |
C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140 |
| Jessica Baker Flechtner |
officer: VP of Research |
C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140 |
| Carmen Chang |
10 percent owner |
2855 SAND HILL ROAD, MENLO PARK CA 94025 |
| New Enterprise Associates 16, L.p. |
10 percent owner |
1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
| Paul Edward Walker |
10 percent owner |
1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
| Mohamad Makhzoumi |
10 percent owner |
2855 SAND HILL ROAD, MENLO PARK CA 94025 |
| Ali Behbahani |
director |
5425 WISCONSIN AVE, CHEVY CHASE MD 20815 |
| Forest Baskett |
10 percent owner |
|
| Peter W. Sonsini |
10 percent owner |
2855 SAND HILL ROAD, MENLO PARK CA 94025 |
| Florence Anthony A. Jr. |
10 percent owner |
5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815 |
Genocea Biosciences (Genocea Biosciences) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GNCAQ has been successfully added to your